Diabetes mellitus and hepatitis C

Česká verzia

Authors: Petr Husa; Petr Husa Jr
Authors place of work: Klinika infekčních chorob LF MU a FN Brno, pracoviště Bohunice
Published in the journal: Forum Diab 2016; 5(3): 134-136
Category: Foreign Post

Summary

Extrahepatic manifestations of hepatitis C virus infection (HCV) are very common. A link with the HCV infection is considered to be established with membranoproliferative glomerulonephritis, leukocytoclastic vasculitis, lymphoproliferative disorders (in particular B-cell lymphoma), Sjögren and sicca syndrome, lichen planus, porfyria cutanea tarda and diabetes mellitus. Antiviral therapy may prevent progression to diabetes in patients with prediabetes who have hepatitis C and may reduce renal and cardiovascular complications in patients with established diabetes who have hepatitis C.

Key words:
extrahepatic manifestations – chronic hepatitis C – direct acting antivirals

Zdroje

1. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2016. Summary. Dostupné z WWW: <http://www.easl.eu/medias/cpg/HCV2016/Summary.pdf>.

2. Tillmann HL, McHutchison JG. Hepatitis C. In: Boyer TD, Manns MP, Sanyal A. Zakim and Boyer´s Hepatology: A Textbook of Liver Disease. 6th ed. Elsevier Saunders: Philadelphia 2012: 574–576. ISBN 978–1437708813.

3. American Association for the study of Liver Diseases (AASLD). HCV Guidance: Recommendation for testing, managing, and treating hepatitis C. Dostupné z WWW: <http://www.hcvguidelines.org/>.

4. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes. A systematic review and meta-analysis. J Hepatol 2008; 49(5): 831–844. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2008.08.006>.

5. Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133(8): 592–599.

6. Yoneda M, Saito S, Ikeda T et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat 2007; 14(9): 600–607.

7. Petta S, Camma C, Di Marco V et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103(5): 1136–1144. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1572–0241.2008.01813.x>.

8. Hung CH, Wang JH, Hu TH et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16(18): 2265–2271.

9. Arase Y, Suzuki F, Suzuki Y et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49(3): 739–744. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.22703>.

10. Hsu YC, Lin JT, Ho HJ et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59(4): 1293–1302. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.26892>.

11. Hsu YC, Ho HJ, Huang YT et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64(3): 495–503. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2014–308163>.

12. University of Liverpool. Drug interactions charts. Dostupné z WWW: <http://www.hep-druginteractions.org/>.